Awareness of the Harms of Continued Smoking Among Cancer Survivors.


Journal

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 15 03 2019
accepted: 05 11 2019
pubmed: 30 11 2019
medline: 28 7 2020
entrez: 30 11 2019
Statut: ppublish

Résumé

Smoking cessation is an integral part of cancer survivorship. To help improve survivorship education, clinicians need an understanding of patient awareness of the harms of continued smoking. Cancer survivors from Princess Margaret Cancer Centre (Toronto, ON) were surveyed on their awareness of the harms of continued smoking on cancer-related outcomes. Multivariable logistic regression models assessed factors associated with awareness and whether awareness was associated with subsequent cessation among smokers at diagnosis. Among 1118 patients, 23% were current smokers pre-diagnosis and 54% subsequently quit; 25% had lung and 30% head and neck cancers. Many patients reported being unaware that continued smoking results in greater cancer surgical complications (53%), increased radiation side effects (62%), decreased quality of life during chemotherapy (51%), decreased chemotherapy or radiation efficacy (57%), increased risk of death (40%), and increased development of second primaries (38%). Being a current smoker was associated with greater lack of awareness of some of these smoking harms (aORs = 1.53-2.20, P < 0.001-0.02), as was exposure to any second-hand smoke (aORs = 1.45-1.53, P = 0.006-0.04) and being diagnosed with early stage cancer (aORs = 1.38-2.31, P < 0.001-0.06). Among current smokers, those with fewer pack-years, being treated for cure, or had a non-tobacco-related cancer were more likely unaware. Awareness that continued tobacco use worsen quality of life after chemotherapy was associated with subsequent cessation (aOR = 2.26, P = 0.006). Many cancer survivors are unaware that continued smoking can negatively impact cancer-related outcomes. The impact of educating patients about the potential harms of continued smoking when discussing treatment plans should be further evaluated.

Sections du résumé

BACKGROUND BACKGROUND
Smoking cessation is an integral part of cancer survivorship. To help improve survivorship education, clinicians need an understanding of patient awareness of the harms of continued smoking.
METHODS METHODS
Cancer survivors from Princess Margaret Cancer Centre (Toronto, ON) were surveyed on their awareness of the harms of continued smoking on cancer-related outcomes. Multivariable logistic regression models assessed factors associated with awareness and whether awareness was associated with subsequent cessation among smokers at diagnosis.
RESULTS RESULTS
Among 1118 patients, 23% were current smokers pre-diagnosis and 54% subsequently quit; 25% had lung and 30% head and neck cancers. Many patients reported being unaware that continued smoking results in greater cancer surgical complications (53%), increased radiation side effects (62%), decreased quality of life during chemotherapy (51%), decreased chemotherapy or radiation efficacy (57%), increased risk of death (40%), and increased development of second primaries (38%). Being a current smoker was associated with greater lack of awareness of some of these smoking harms (aORs = 1.53-2.20, P < 0.001-0.02), as was exposure to any second-hand smoke (aORs = 1.45-1.53, P = 0.006-0.04) and being diagnosed with early stage cancer (aORs = 1.38-2.31, P < 0.001-0.06). Among current smokers, those with fewer pack-years, being treated for cure, or had a non-tobacco-related cancer were more likely unaware. Awareness that continued tobacco use worsen quality of life after chemotherapy was associated with subsequent cessation (aOR = 2.26, P = 0.006).
CONCLUSIONS CONCLUSIONS
Many cancer survivors are unaware that continued smoking can negatively impact cancer-related outcomes. The impact of educating patients about the potential harms of continued smoking when discussing treatment plans should be further evaluated.

Identifiants

pubmed: 31781945
doi: 10.1007/s00520-019-05175-4
pii: 10.1007/s00520-019-05175-4
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3409-3419

Auteurs

Lawson Eng (L)

Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre/University Health Network and University of Toronto, Toronto, Ontario, Canada.
Ontario Cancer Institute, Toronto, Ontario, Canada.
Department of Medicine, University Health Network, Toronto, Ontario, Canada.

Devon Alton (D)

Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre/University Health Network and University of Toronto, Toronto, Ontario, Canada.
Ontario Cancer Institute, Toronto, Ontario, Canada.
Department of Medicine, University Health Network, Toronto, Ontario, Canada.
Department of Radiation Oncology, Princess Margaret Cancer Centre, 610 University Ave, Rm 7-125, Toronto, Ontario, M5G 2M9, Canada.

Yuyao Song (Y)

Ontario Cancer Institute, Toronto, Ontario, Canada.
Department of Biostatistics, Princess Margaret Cancer Centre/University Health Network and University of Toronto, Toronto, Ontario, Canada.

Jie Su (J)

Ontario Cancer Institute, Toronto, Ontario, Canada.
Department of Biostatistics, Princess Margaret Cancer Centre/University Health Network and University of Toronto, Toronto, Ontario, Canada.

Qihuang Zhang (Q)

Department of Biostatistics, Princess Margaret Cancer Centre/University Health Network and University of Toronto, Toronto, Ontario, Canada.

Jiahua Che (J)

Department of Biostatistics, Princess Margaret Cancer Centre/University Health Network and University of Toronto, Toronto, Ontario, Canada.

Delaram Farzanfar (D)

Ontario Cancer Institute, Toronto, Ontario, Canada.

Rahul Mohan (R)

Ontario Cancer Institute, Toronto, Ontario, Canada.

Olivia Krys (O)

Ontario Cancer Institute, Toronto, Ontario, Canada.

Katie Mattina (K)

Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre/University Health Network and University of Toronto, Toronto, Ontario, Canada.
Ontario Cancer Institute, Toronto, Ontario, Canada.

Christopher Harper (C)

Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre/University Health Network and University of Toronto, Toronto, Ontario, Canada.
Ontario Cancer Institute, Toronto, Ontario, Canada.

Sophia Liu (S)

Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre/University Health Network and University of Toronto, Toronto, Ontario, Canada.
Ontario Cancer Institute, Toronto, Ontario, Canada.

Tom Yoannidis (T)

Department of Otolaryngology-Head and Neck Surgery, University of Toronto, University Health Network, Toronto, Ontario, Canada.

Robin Milne (R)

Ontario Cancer Institute, Toronto, Ontario, Canada.
Department of Radiation Oncology, Princess Margaret Cancer Centre, 610 University Ave, Rm 7-125, Toronto, Ontario, M5G 2M9, Canada.

Nazek Abdelmutti (N)

Department of Radiation Oncology, Princess Margaret Cancer Centre, 610 University Ave, Rm 7-125, Toronto, Ontario, M5G 2M9, Canada.

M Catherine Brown (MC)

Ontario Cancer Institute, Toronto, Ontario, Canada.

Ashlee Vennettilli (A)

Ontario Cancer Institute, Toronto, Ontario, Canada.

Andrew J Hope (AJ)

Department of Radiation Oncology, Princess Margaret Cancer Centre, 610 University Ave, Rm 7-125, Toronto, Ontario, M5G 2M9, Canada.

Doris Howell (D)

Ontario Cancer Institute, Toronto, Ontario, Canada.

Jennifer M Jones (JM)

Ontario Cancer Institute, Toronto, Ontario, Canada.

Peter Selby (P)

Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.
Departments of Family and Community Medicine & Psychiatry, University of Toronto, Toronto, Canada.

William K Evans (WK)

Division of Medical Oncology, Department of Oncology, McMaster University, Hamilton, Ontario, Canada.

Wei Xu (W)

Ontario Cancer Institute, Toronto, Ontario, Canada.
Department of Medicine, University Health Network, Toronto, Ontario, Canada.
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

David Paul Goldstein (DP)

Department of Otolaryngology-Head and Neck Surgery, University of Toronto, University Health Network, Toronto, Ontario, Canada.

Meredith Elana Giuliani (ME)

Ontario Cancer Institute, Toronto, Ontario, Canada. Meredith.Giuliani@rmp.uhn.ca.
Department of Radiation Oncology, Princess Margaret Cancer Centre, 610 University Ave, Rm 7-125, Toronto, Ontario, M5G 2M9, Canada. Meredith.Giuliani@rmp.uhn.ca.

Geoffrey Liu (G)

Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre/University Health Network and University of Toronto, Toronto, Ontario, Canada. geoffrey.liu@uhn.ca.
Ontario Cancer Institute, Toronto, Ontario, Canada. geoffrey.liu@uhn.ca.
Department of Medicine, University Health Network, Toronto, Ontario, Canada. geoffrey.liu@uhn.ca.
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. geoffrey.liu@uhn.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH